Cargando…

LPTO-04. GENERATION AND CHARACTERIZATION OF PATIENT-DERIVED PRECLINICAL MODELS FROM TUMOR CELLS ISOLATED FROM CEREBROSPINAL FLUID

BACKGROUND: CNS metastases occur in 20–50% of lung cancer patients during their disease; leptomeningeal disease (LMD) representing 5–8%, classically carries a poor prognosis with a median overall survival ranging from 1–11 months. There is a paucity of patient-derived preclinical disease models usin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Offin, Michael, Vojnic, Morana, Liu, Zebing, Lui, Allan, Siau, Evan, Gladstone, Eric, Mattar, Marissa, Khodos, Inna, Drilon, Alexander, Boire, Adrienne, Rudin, Charles, De Stanchina, Elisa, Ladanyi, Marc, Somwar, Romel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213369/ http://dx.doi.org/10.1093/noajnl/vdz014.027

Ejemplares similares

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
por: Somwar, Romel, et al.
Publicado: (2020)

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
por: Hayashi, Takuo, et al.
Publicado: (2021)

CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma
por: Odintsov, Igor, et al.
Publicado: (2022)

Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling
por: Smith, Roger S., et al.
Publicado: (2022)

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
por: Schram, Alison M., et al.
Publicado: (2022)

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer
por: Suzawa, Ken, et al.
Publicado: (2019)

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
por: Miyazaki, Isao, et al.
Publicado: (2023)

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
por: Miyazaki, Isao, et al.
Publicado: (2023)

LPTO-07. CARCINOEMBRYONIC ANTIGEN OF CEREBROSPINAL FLUID PREDICT PROGNOSIS OF LEPTOMENINGEAL METASTASIS FROM NON-SMALL CELL LUNG CANCER
por: Zhen, Junjie, et al.
Publicado: (2019)

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers
por: Drilon, Alexander, et al.
Publicado: (2016)

LPTO-09. INTRATHECAL TOPOTECAN FOR LEPTOMENINGEAL METASTASIS IN SOLID TUMORS: THE MD ANDERSON EXPERIENCE
por: Sinicrope, Kaylyn D, et al.
Publicado: (2019)

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
por: Farnsworth, Dylan A., et al.
Publicado: (2022)

LPTO-01. LEPTOMENINGEAL METASTASIS FROM OVARIAN CARCINOMA TREATED WITH SYSTEMIC HIGH-DOSE METHOTREXATE
por: Coffee, Elizabeth, et al.
Publicado: (2019)

Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance
por: Ogura, Koichi, et al.
Publicado: (2022)

LPTO-06. A NOVEL BRAIN-PERMEANT CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS
por: Deng, Jiaojiao, et al.
Publicado: (2019)

LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY
por: Williams, Nicole, et al.
Publicado: (2019)

Serendipitous Finding of Asymptomatic Babesiosis in a Patient With Symptomatic Thrombocytopenia
por: Anand, Lalitha, et al.
Publicado: (2019)

LPTO-03. IN-VITRO & IN-VIVO CULTURE OF PATIENT (PT) DERIVED CSF-CTCs IN LEPTOMENINGEAL DISEASE (LMDz) FROM MELANOMA TO IDENTIFY NOVEL TREATMENT STRATEGIES
por: Law, Vincent, et al.
Publicado: (2019)

LptO (PG0027) Is Required for Lipid A 1-Phosphatase Activity in Porphyromonas gingivalis W50
por: Rangarajan, Minnie, et al.
Publicado: (2017)

LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS
por: Trevino, Christopher R, et al.
Publicado: (2019)

Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation
por: Cocco, Emiliano, et al.
Publicado: (2019)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
por: Gong, Yixuan, et al.
Publicado: (2007)

A blast from the past: ROS1 on the brain
por: Odintsov, Igor, et al.
Publicado: (2019)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

LPTO-05. FACTORS INFLUENCING RISK OF LEPTOMENINGEAL METASTASIS IN BREAST CANCER PATIENTS RECEIVING STEREOTACTIC RADIOSURGERY FOR LIMITED BRAIN METASTASES
por: Zhang, Michael, et al.
Publicado: (2019)

Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer
por: Inoue, Yusuke, et al.
Publicado: (2021)

Desmoplastic small round cell tumor cancer stem cell-like cells resist chemotherapy but remain dependent on the EWSR1-WT1 oncoprotein
por: Magrath, Justin W., et al.
Publicado: (2022)

Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation
por: Choo, Florence, et al.
Publicado: (2022)

Mature Type T-Lymphoblastic Leukemia/Lymphoma Presenting With Isolated Central Nervous System Symptomatology in a Patient With Giant Cell Arteritis on Long-Term Steroid Treatment
por: Smith, John Kolton, et al.
Publicado: (2023)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library
por: Offin, Michael, et al.
Publicado: (2022)

Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do?
por: Goyal, Shreya Prasad, et al.
Publicado: (2021)

SDPS-25 COMPARISON OF MOLECULAR ALTERATIONS BETWEEN SYSTEMIC AND CNS METASTATIC SITES REVEALSMUTATIONAL DISCORDANCES
por: Huang, David, et al.
Publicado: (2023)

Brain metastasis screening in the molecular age
por: Tabor, Joanna K, et al.
Publicado: (2023)

Establishing and Maintaining an Extensive Library of Patient-Derived Xenograft Models
por: Mattar, Marissa, et al.
Publicado: (2018)

OMIC-04. IDENTIFICATION AND CHARACTERIZATION OF CIRCULATING RNAS (CODING AND NONCODING) AND METABOLITES IN CEREBROSPINAL FLUID IN MEDULLOBLASTOMA PATIENTS
por: Lee, Bongyong, et al.
Publicado: (2021)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY
por: Kumthekar, Priya, et al.
Publicado: (2019)

MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis
por: Lu, Daniel, et al.
Publicado: (2022)

EXM-86-04: 17/04/1986
por: Malandain, E.
Publicado: (1986)

Cannot write session to /tmp/vufind_sessions/sess_qji9gorpiigd8nputi6ufq51ak